Cargando…

Mild Cognitive Impairment with a High Risk of Progression to Alzheimer’s Disease Dementia (MCI-HR-AD): Effect of Souvenaid(®) Treatment on Cognition and (18)F-FDG PET Scans

BACKGROUND: Previous studies have shown that Souvenaid (medical food) can have benefits on memory, cognition, and function in early Alzheimer’s disease (AD) and mild cognitive impairment (MCI). OBJECTIVE: Demonstrate that Souvenaid could improve or maintain cognition and has an effect on neurodegene...

Descripción completa

Detalles Bibliográficos
Autores principales: Manzano Palomo, Maria Sagrario, Anaya Caravaca, Belen, Balsa Bretón, Maria Angeles, Castrillo, Sergio Muñiz, Vicente, Asuncion de la Morena, Castro Arce, Eduardo, Alves Prez, María Teresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6597964/
https://www.ncbi.nlm.nih.gov/pubmed/31259306
http://dx.doi.org/10.3233/ADR-190109
_version_ 1783430674142724096
author Manzano Palomo, Maria Sagrario
Anaya Caravaca, Belen
Balsa Bretón, Maria Angeles
Castrillo, Sergio Muñiz
Vicente, Asuncion de la Morena
Castro Arce, Eduardo
Alves Prez, María Teresa
author_facet Manzano Palomo, Maria Sagrario
Anaya Caravaca, Belen
Balsa Bretón, Maria Angeles
Castrillo, Sergio Muñiz
Vicente, Asuncion de la Morena
Castro Arce, Eduardo
Alves Prez, María Teresa
author_sort Manzano Palomo, Maria Sagrario
collection PubMed
description BACKGROUND: Previous studies have shown that Souvenaid (medical food) can have benefits on memory, cognition, and function in early Alzheimer’s disease (AD) and mild cognitive impairment (MCI). OBJECTIVE: Demonstrate that Souvenaid could improve or maintain cognition and has an effect on neurodegeneration biomarkers. METHODS: This cohort study was carried out from June 2015 through December 2016 in the Neurology Department, Infanta Cristina Hospital, Madrid, Spain. MCI-HR-AD were recruited using Petersen criteria, neuropsychology (NPS), and (18)F-FDG PET scans to confirm the high risk of progression to dementia with one year of follow-up. Age, sex, vascular risk factors (VRF), and NPS values (Barcelona brief version) were analyzed. (18)F-FDG PET scans were analyzed as a visual procedure. The study was approved by the Research Committee of ICH. Statistical analysis was made with SPSS 22.0 version. RESULTS: Subjects included 43 MCI patients (58.5% women; mean age 69.78±7.89): 17 receiving Souvenaid(®) treatment (ST), 24 receiving no treatment (WT) and 2 who withdrew. No differences were seen in VRF, only hypercholesterolemia, and were less prevalent in the ST group (p = 0.002). The rate of progression to dementia was 48.8% (no differences between groups, p = 0.654). A second round of (18)F-FDG PET scans showed a significance worsening of glucose metabolism in WT (p = 0.001) versus ST, in which it was low (p = 0.050). For NPS testing, there was a significant worsening in memory performance in the WT group (p = 0.011) and a stabilization in ST (p = 0.083), as well as in executive functions and attention (worsening in WT, p = 0.014). For the Subjective Changing Scale (SCS), caregivers indicated a stabilization/improvement in ST (p = 0.017). CONCLUSION: Souvenaid had a significant effect on several cognitive domains, and on SCS in patients with MCI-HR-AD. Its intervention had an impact on preservation on (18)F-FDG PET scans.
format Online
Article
Text
id pubmed-6597964
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher IOS Press
record_format MEDLINE/PubMed
spelling pubmed-65979642019-06-28 Mild Cognitive Impairment with a High Risk of Progression to Alzheimer’s Disease Dementia (MCI-HR-AD): Effect of Souvenaid(®) Treatment on Cognition and (18)F-FDG PET Scans Manzano Palomo, Maria Sagrario Anaya Caravaca, Belen Balsa Bretón, Maria Angeles Castrillo, Sergio Muñiz Vicente, Asuncion de la Morena Castro Arce, Eduardo Alves Prez, María Teresa J Alzheimers Dis Rep Research Report BACKGROUND: Previous studies have shown that Souvenaid (medical food) can have benefits on memory, cognition, and function in early Alzheimer’s disease (AD) and mild cognitive impairment (MCI). OBJECTIVE: Demonstrate that Souvenaid could improve or maintain cognition and has an effect on neurodegeneration biomarkers. METHODS: This cohort study was carried out from June 2015 through December 2016 in the Neurology Department, Infanta Cristina Hospital, Madrid, Spain. MCI-HR-AD were recruited using Petersen criteria, neuropsychology (NPS), and (18)F-FDG PET scans to confirm the high risk of progression to dementia with one year of follow-up. Age, sex, vascular risk factors (VRF), and NPS values (Barcelona brief version) were analyzed. (18)F-FDG PET scans were analyzed as a visual procedure. The study was approved by the Research Committee of ICH. Statistical analysis was made with SPSS 22.0 version. RESULTS: Subjects included 43 MCI patients (58.5% women; mean age 69.78±7.89): 17 receiving Souvenaid(®) treatment (ST), 24 receiving no treatment (WT) and 2 who withdrew. No differences were seen in VRF, only hypercholesterolemia, and were less prevalent in the ST group (p = 0.002). The rate of progression to dementia was 48.8% (no differences between groups, p = 0.654). A second round of (18)F-FDG PET scans showed a significance worsening of glucose metabolism in WT (p = 0.001) versus ST, in which it was low (p = 0.050). For NPS testing, there was a significant worsening in memory performance in the WT group (p = 0.011) and a stabilization in ST (p = 0.083), as well as in executive functions and attention (worsening in WT, p = 0.014). For the Subjective Changing Scale (SCS), caregivers indicated a stabilization/improvement in ST (p = 0.017). CONCLUSION: Souvenaid had a significant effect on several cognitive domains, and on SCS in patients with MCI-HR-AD. Its intervention had an impact on preservation on (18)F-FDG PET scans. IOS Press 2019-05-03 /pmc/articles/PMC6597964/ /pubmed/31259306 http://dx.doi.org/10.3233/ADR-190109 Text en © 2019 – IOS Press and the authors. All rights reserved https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) License (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Report
Manzano Palomo, Maria Sagrario
Anaya Caravaca, Belen
Balsa Bretón, Maria Angeles
Castrillo, Sergio Muñiz
Vicente, Asuncion de la Morena
Castro Arce, Eduardo
Alves Prez, María Teresa
Mild Cognitive Impairment with a High Risk of Progression to Alzheimer’s Disease Dementia (MCI-HR-AD): Effect of Souvenaid(®) Treatment on Cognition and (18)F-FDG PET Scans
title Mild Cognitive Impairment with a High Risk of Progression to Alzheimer’s Disease Dementia (MCI-HR-AD): Effect of Souvenaid(®) Treatment on Cognition and (18)F-FDG PET Scans
title_full Mild Cognitive Impairment with a High Risk of Progression to Alzheimer’s Disease Dementia (MCI-HR-AD): Effect of Souvenaid(®) Treatment on Cognition and (18)F-FDG PET Scans
title_fullStr Mild Cognitive Impairment with a High Risk of Progression to Alzheimer’s Disease Dementia (MCI-HR-AD): Effect of Souvenaid(®) Treatment on Cognition and (18)F-FDG PET Scans
title_full_unstemmed Mild Cognitive Impairment with a High Risk of Progression to Alzheimer’s Disease Dementia (MCI-HR-AD): Effect of Souvenaid(®) Treatment on Cognition and (18)F-FDG PET Scans
title_short Mild Cognitive Impairment with a High Risk of Progression to Alzheimer’s Disease Dementia (MCI-HR-AD): Effect of Souvenaid(®) Treatment on Cognition and (18)F-FDG PET Scans
title_sort mild cognitive impairment with a high risk of progression to alzheimer’s disease dementia (mci-hr-ad): effect of souvenaid(®) treatment on cognition and (18)f-fdg pet scans
topic Research Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6597964/
https://www.ncbi.nlm.nih.gov/pubmed/31259306
http://dx.doi.org/10.3233/ADR-190109
work_keys_str_mv AT manzanopalomomariasagrario mildcognitiveimpairmentwithahighriskofprogressiontoalzheimersdiseasedementiamcihradeffectofsouvenaidtreatmentoncognitionand18ffdgpetscans
AT anayacaravacabelen mildcognitiveimpairmentwithahighriskofprogressiontoalzheimersdiseasedementiamcihradeffectofsouvenaidtreatmentoncognitionand18ffdgpetscans
AT balsabretonmariaangeles mildcognitiveimpairmentwithahighriskofprogressiontoalzheimersdiseasedementiamcihradeffectofsouvenaidtreatmentoncognitionand18ffdgpetscans
AT castrillosergiomuniz mildcognitiveimpairmentwithahighriskofprogressiontoalzheimersdiseasedementiamcihradeffectofsouvenaidtreatmentoncognitionand18ffdgpetscans
AT vicenteasunciondelamorena mildcognitiveimpairmentwithahighriskofprogressiontoalzheimersdiseasedementiamcihradeffectofsouvenaidtreatmentoncognitionand18ffdgpetscans
AT castroarceeduardo mildcognitiveimpairmentwithahighriskofprogressiontoalzheimersdiseasedementiamcihradeffectofsouvenaidtreatmentoncognitionand18ffdgpetscans
AT alvesprezmariateresa mildcognitiveimpairmentwithahighriskofprogressiontoalzheimersdiseasedementiamcihradeffectofsouvenaidtreatmentoncognitionand18ffdgpetscans